MedTrace Logo

Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

NCT04830215 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2024-02-02

Study results available
· View outcomes & findings →

Summary

The clinical trial will investigate the effect of brexpiprazole on the concept of life engagement in participants with Major Depressive Disorder (MDD) with a current depressive episode.

Conditions

Interventions

DRUG

Brexpiprazole

Oral brexpiprazole tablets as adjunctive therapy to ADT

Sponsors & Collaborators

  • Lundbeck Canada Inc.

    collaborator INDUSTRY

  • Otsuka Canada Pharmaceutical Inc.

    collaborator INDUSTRY

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    lead INDUSTRY

Principal Investigators

  • Eva Kohegyi, MD · Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-05-27
Completion
2022-05-27

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04830215 on ClinicalTrials.gov